WP 2 : Lipids in cancer and treatments

WP 2 : Lipids in cancer and treatments | Responsable : Mickaël Rialland

The goal of workpackage 2 is to better understand the role of dietary lipids, extracellular vesicles-associated lipids and lipid metabolism in initiation, progression and treatments of cancers.

Lipids are a complex group of macromolecules involved in structural, energetic and signaling functions. Alteration of lipid metabolism is a hallmark of cancers and impacts the response to anti-cancer therapies. The lipid metabolic rewiring concerns synthesis, uptake, degradation, storage and modification of lipids, and is a feature of the high cancer cell plasticity to adapt to tumor microenvironment. Additionally, the release of lipids or extracellular vesicles-associated lipid mediators modulates bidirectional crosstalk between cancer cells and cells of the microenvironment (e.g. immune cells) affecting cancer progression. Studies currently initiated by LipSTIC teams are identification of exosomes as biomarkers to evaluate tumor progression or therapy response (e.g. breast, lung and bladder cancers, HPV-associated cancers) and the role of epigenetic modifications-regulated lipid metabolism in cancers (breast cancer and leukemia). New projects are investigating the function of phospholipid remodeling and fatty acid modifications in initiation of cancer and chemoresistance (hepatocarcinogenesis, colon and breast cancers). Furthermore, LipSTIC teams of workpackage 2 are experts in oncoimmunology and are analyzing the link between lipid rafts and activation of lymphocytes, inflammation actors and cancer, and function of exosomes in immunotherapy. Moreover, several studies report pro- or anti-tumoral properties of dietary lipids. In the workpackage 2, teams are determining effects of dietary or pharmacological interventions that target lipid metabolism for improving cancer treatments.

Main objectives :

  • Identification of lipid metabolic and signaling pathway(s) involved in the initiation, progression and resistance to anti-cancer therapies (chemo and immunotherapy)
  • Identification of the role of lipids and inflammation on tumor-infiltrating immune cells and their modulation to improve anti-tumoral responses (chemo and immunotherapy)
  • Development of a diagnostic tools based on the capture of HSP70-expressing exosomes coupled to lipidomic analysis
  • Development of market innovative therapeutic strategies, new drugs, new diagnostic tools


Les équipes concernées :

EA3181

Carcinogenèse associée aux HPV : facteurs prédictifs et pronostiques


Besançon
UMR1098 Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique

Thérapeutique ImmunoMoléculaire des Cancers (TIM-C)


Besançon
UMR1231

Lipness (lipid and lipid transfer in sterile and septic inflammation


Dijon
UMR1231 Lipides, Nutrition, Cancer

Cancer and ADative Immune Response – CADIR


Dijon
Centre des Sciences du Goût et de l’Alimentation (CSGA) UMR1324 INRAE, 6265CNRS, Universite Bourgogne-Franche-Comté, AgroSup Dijon

Équipe Œil, Nutrition et Signalisation Cellulaire


Dijon
UMR1231 Lipides, Nutrition, Cancer

Physiopathologie des dyslipidémies – PADYS


Dijon
UMR1231 Lipides, Nutrition, Cancer

EPICAD : ÉPIdémiologie et recherche Clinique en cAncérologie Digestive


Dijon
UMR1231 Lipides, Nutrition, Cancer

Régulation de la différenciation lymphocytaire T CD4 par les acides nucléiques – CD4DNA


Dijon
Centre d’Investigation Clinique de Dijon (Inserm CIC1432)

CIC1432


Dijon
UMR1231 Lipides, Nutrition, Cancer

Epigenetics, epidemiology and personalized treatment in hematological malignancies – Epi2THM (ex SAPHIHR)


Dijon